Dr. Steve Chamow Joins GigaGen As Manufacturing Lead
SAN FRANCISCO, CA — GigaGen CEO David Johnson is excited to announce that Steve Chamow, PhD, has joined GigaGen as manufacturing lead. Dr. Chamow will help GigaGen surmount the manufacturing challenges inherent in the development of a recombinant version of IVIG.
Dr. Chamow has more than 20 years of experience in biopharmaceutical product development. A principal consultant, he helps biotechnology companies to develop CMC strategies for products in development and lifecycle strategies for marketed products. Over his career, he contributed to the development of three marketed products (Avastin, Natrecor, Vectibix).
Previously, he served as Senior Vice President, CMC, at Intradigm Corporation, a private biopharmaceutical company focused on developing RNAi therapeutics (acquired by Silence Therapeutics). Prior to Intradigm, Dr. Chamow was Vice President, Process Sciences, at Genitope Corporation and at Abgenix, Inc., (acquired by Amgen) where he built the company’s process sciences department and co-led the design and construction of Abgenix’ award-winning mammalian cell production facility in Fremont, CA.
Before Abgenix, he served as Director of Biopharmaceutical Development at Scios, Inc., (acquired by J&J), and as a scientist and senior scientist in process development at Genentech, Inc. Dr. Chamow was educated at the University of California (UC Santa Cruz, B.A. in biology; UC Davis, Ph.D. in biochemistry), and completed postdoctoral training at the National Institutes of Health. Dr. Chamow is author or co-author of more than 45 scientific publications and patents and co-editor of a 1999 book entitled Antibody Fusion Proteins.